Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics (ATXS)
NASDAQ:ATXS
Astria Therapeutics (ATXS) Stock Price & Analysis
1,007 Followers
ATXS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.26 - $16.90
Previous Close$9.54
Volume291.66K
Average Volume (3M)1.02M
Market Cap
$523.87M
Enterprise Value$154.13M
Total Cash (Recent Filing)$369.91M
Total Debt (Recent Filing)$168.00K
Price to Earnings (P/E)-4.1
Beta0.96
Next Earnings
Aug 05, 2024EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding54,913,061
10 Day Avg. Volume488,577
30 Day Avg. Volume1,015,623
Standard Deviation0.30
R-Squared0.02
Alpha0.00919
Financial Highlights & Ratios
Price to Book (P/B)1.92
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.51
Forecast
1Y Price Target
$25.00Price Target Upside162.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Astria Therapeutics News
PremiumCompany Announcements
Astria Therapeutics Expands Board, Appoints New Director
PremiumCompany Announcements
Astria Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?Bulls Say, Bears Say
Bulls Say
Drug Efficacy And SafetyAstria's lead asset, STAR-0215, has shown impressive efficacy and safety data from its ALPHA-STAR Phase 1b/2 study.
Market PotentialThe HAE market is expected to grow, indicating a larger potential market for STAR-0215 if approved.
Strategic DevelopmentAstria plans to initiate two separate Phase 3 trials with STAR-0215, aiming for an enhanced speed to market.
Bears Say
Equity And ValuationDilution impact from recent equity raises and increased share count must be considered in valuation.
Financial PerformanceAstria reported higher than estimated losses per share with EPS of ($0.86) and ($2.42), exceeding the analyst's estimate of ($0.54) and ($1.93), and consensus of ($0.78) and ($2.28).
Stock PerformanceShares are down significantly in comparison to the sector since the announcement of POC data.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATXS FAQ
What was Astria Therapeutics’s price range in the past 12 months?
Astria Therapeutics lowest stock price was $4.26 and its highest was $16.90 in the past 12 months.
What is Astria Therapeutics’s market cap?
Currently, no data Available
When is Astria Therapeutics’s upcoming earnings report date?
Astria Therapeutics’s upcoming earnings report date is Aug 05, 2024 which is in 77 days.
How were Astria Therapeutics’s earnings last quarter?
Astria Therapeutics released its earnings results on May 09, 2024. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.04.
Is Astria Therapeutics overvalued?
According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued.
Does Astria Therapeutics pay dividends?
Astria Therapeutics does not currently pay dividends.
What is Astria Therapeutics’s EPS estimate?
Astria Therapeutics’s EPS estimate is -$0.38.
How many shares outstanding does Astria Therapeutics have?
Astria Therapeutics has 54,913,060 shares outstanding.
What happened to Astria Therapeutics’s price movement after its last earnings report?
Astria Therapeutics reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -4.326%.
Which hedge fund is a major shareholder of Astria Therapeutics?
Among the largest hedge funds holding Astria Therapeutics’s share is Perceptive Advisors LLC. It holds Astria Therapeutics’s shares valued at 91M.
---
Astria Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (162.05% Upside)
$25.00 (162.05% Upside)
Blogger Sentiment
Bearish
ATXS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 8.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.81%
12-Months-Change
Fundamentals
Return on Equity
-28.19%
Trailing 12-Months
Asset Growth
73.57%
Trailing 12-Months
Company Description
Astria Therapeutics
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.
---
ATXS Company Deck
---
ATXS Earnings Call
Q3 2023
0:00 / 0:00
---
ATXS Stock 12 Month Forecast
Average Price Target
$25.00
▲(162.05% Upside)
Technical Analysis
Best Analysts Covering ATXS
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
+19.65%
reiterated a buy rating 11 days ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +19.65% per trade.
---